Viborg Søren, Søgaard Kirstine Kobberøe, Farkas Dóra Körmendiné, Nørrelund Helene, Pedersen Lars, Sørensen Henrik Toft
Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
Clin Transl Gastroenterol. 2016 Apr 7;7(4):e162. doi: 10.1038/ctg.2016.16.
Lower gastrointestinal (GI) bleeding is a well-known symptom of colorectal cancer (CRC). Whether incident GI bleeding is also a marker of other GI cancers remains unclear.
This nationwide cohort study examined the risk of various GI cancer types in patients with lower GI bleeding. We used Danish medical registries to identify all patients with a first-time hospital diagnosis of lower GI bleeding during 1995-2011 and followed them for 10 years to identify subsequent GI cancer diagnoses. We computed absolute risks of cancer, treating death as a competing risk, and calculated standardized incidence ratios (SIRs) by comparing observed cancer cases with expected cancer incidence rates in the general population.
Among 58,593 patients with lower GI bleeding, we observed 2,806 GI cancers during complete 10-year follow-up. During the first year of follow-up, the absolute GI cancer risk was 3.6%, and the SIR of any GI cancer was 16.3 (95% confidence interval (CI): 15.6-17.0). Colorectal cancers accounted for the majority of diagnoses, but risks of all GI cancers were increased. During 1-5 years of follow-up, the SIR of any GI cancer declined to 1.36 (95% CI: 1.25-1.49), but risks remained increased for several GI cancers. Beyond 5 years of follow-up, the overall GI cancer risk was close to unity, with reduced risk of rectal cancer and increased risk of liver and pancreatic cancers.
A hospital-based diagnosis of lower GI bleeding is a strong clinical marker of prevalent GI cancer, particularly CRC. It also predicts an increased risk of any GI cancer beyond 1 year of follow-up.
下消化道(GI)出血是结直肠癌(CRC)的一个众所周知的症状。偶发性GI出血是否也是其他GI癌症的一个标志物仍不清楚。
这项全国性队列研究调查了下消化道出血患者发生各种GI癌症类型的风险。我们利用丹麦医疗登记系统确定了1995年至2011年间首次因下消化道出血而住院诊断的所有患者,并对他们进行了10年的随访,以确定随后的GI癌症诊断情况。我们计算了癌症的绝对风险,将死亡视为竞争风险,并通过将观察到的癌症病例与一般人群中的预期癌症发病率进行比较来计算标准化发病率(SIRs)。
在58593名下消化道出血患者中,在完整的10年随访期间我们观察到2806例GI癌症。在随访的第一年,GI癌症的绝对风险为3.6%,任何GI癌症的SIR为16.3(95%置信区间(CI):15.6 - 17.0)。结直肠癌占诊断病例的大多数,但所有GI癌症的风险均有所增加。在随访的1至5年期间,任何GI癌症的SIR降至1.36(95% CI:1.25 - 1.49),但几种GI癌症的风险仍然增加。随访5年后,总体GI癌症风险接近1,直肠癌风险降低,而肝癌和胰腺癌风险增加。
基于医院的下消化道出血诊断是现存GI癌症尤其是CRC的一个强有力的临床标志物。它还预测了随访1年后任何GI癌症风险的增加。